top of page

Research Roundup: Apr 9, 2024

Best of cannabinoid science this week...

In patients with Parkinson's disease, six months of treatment with nabilone (a synthetic mimic of THC) improved overall sleep, night time sleep problems & overall pain

Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease

A scoping review of patients with hidradenitis suppurativa (an inflammatory skin condition of painful nodules, abscesses & deep scarring) find its widespread use for pain management

Cannabis Usage Among Patients With Hidradenitis Suppurativa: A Scoping Review

In patients with COVID-19, a retrospective analysis found that cannabis users had better clinical outcomes compared with non-users including a decreased need for ICU admission or mechanical ventilation

Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis

A double-blind test of a cannabis oil with 100 milligrams of CBD & 5 milligrams of THC showed people to do worse on memory tests but better on happiness tests

A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood

In dogs, giving them CBD rich extracts reduced their necessary anesthetic dosage of propofol by 23%

Full spectrum cannabidiol-rich extract reduced propofol dosage required for anesthetic induction in dogs—a pilot study

A review of using CBD & the other cannabinoids for epilepsy MS, & Parkinson's disease as well as the psychiatric disorders that go with them

Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

A review of the topical use of cannabinoids for humans & animals

An Insight into the Use of Cannabis in Medical and Veterinary Dermatological Applications and its Legal Regulation

For patients with epilepsy, a review of how CBD moves through their system & how well it works

Cannabidiol: metabolism and clinical efficacy in epileptic patients

A review of the terpene beta-caryophyllene for emotional & cognitive disorders

Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders

In mouse models, CBD caused anti-anxiety (apparently mediated by the serotonin 5-HT1A receptor) & antipsychotic like effects (apparently mediated by norepinephrine & GABA)

Cannabidiol exhibits anxiolytic-like effects and antipsychotic-like effects in mice models

In the heart tissue of rats with too much insulin (hyperinsulinemia), THC protected against oxidative stress, inflammation & apoptosis (program cellular suicide)

Δ(9)-tetrahydrocannabinol protects cardiac tissue against endoplasmic reticulum and oxidative stresses, apoptosis, and inflammation in rats with hyperinsulinemia

In a skin tissue model of psoriasis, CBD shifted the immune system to a less inflammatory response

Cannabidiol exerts multitarget immunomodulatory effects on PBMCs from individuals with psoriasis vulgaris

How CBC is metabolized by the liver enzymes

Elucidating the Mechanism of Metabolism of Cannabichromene by Human Cytochrome P450s


bottom of page